{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:09:10Z","timestamp":1789229350265,"version":"build-2803163510"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2022-MS-209"],"award-info":[{"award-number":["2022-MS-209"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"2023 China Medical University High-quality Development Fund","award":["2023JH2\/20200119"],"award-info":[{"award-number":["2023JH2\/20200119"]}]},{"name":"Henan Pediatric Disease Clinical Medical Research Center Foundation","award":["YJZX202207"],"award-info":[{"award-number":["YJZX202207"]}]},{"name":"CAAE Epilepsy Research Fund","award":["CX-B-2021-02"],"award-info":[{"award-number":["CX-B-2021-02"]}]},{"name":"Medical Education Research Project of Liaoning Province","award":["2022-N004-09"],"award-info":[{"award-number":["2022-N004-09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12035-024-04501-0","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:02:44Z","timestamp":1727449364000},"page":"3863-3876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacologically Targeting Ferroptosis and Cuproptosis in Neuroblastoma"],"prefix":"10.1007","volume":"62","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"9579","key":"4501_CR1","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","volume":"369","author":"JM Maris","year":"2007","unstructured":"Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma Lancet 369(9579):2106\u20132120. https:\/\/doi.org\/10.1016\/S0140-6736(07)60983-0","journal-title":"Neuroblastoma Lancet"},{"key":"4501_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.critrevonc.2019.03.013","volume":"138","author":"ER Pastor","year":"2019","unstructured":"Pastor ER, Mousa SA (2019) Current management of neuroblastoma and future direction. Crit Rev Oncol Hematol 138:38\u201343. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.03.013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"4501_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","volume":"19","author":"B Qiu","year":"2022","unstructured":"Qiu B, Matthay KK (2022) Advancing therapy for neuroblastoma. Nat Rev Clin Oncol 19(8):515\u2013533. https:\/\/doi.org\/10.1038\/s41571-022-00643-z","journal-title":"Nat Rev Clin Oncol"},{"key":"4501_CR4","doi-asserted-by":"publisher","first-page":"7394268","DOI":"10.1155\/2018\/7394268","volume":"2018","author":"IV Kholodenko","year":"2018","unstructured":"Kholodenko IV, Kalinovsky DV, Doronin II, Deyev SM, Kholodenko RV (2018) Neuroblastoma origin and therapeutic targets for immunotherapy. J Immunol Res 2018:7394268. https:\/\/doi.org\/10.1155\/2018\/7394268","journal-title":"J Immunol Res"},{"issue":"5","key":"4501_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/pbc.24350","volume":"60","author":"AS Pai Panandiker","year":"2013","unstructured":"Pai Panandiker AS, Beltran C, Billups CA, McGregor LM, Furman WL, Davidoff AM (2013) Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma. Pediatr Blood Cancer 60(5):761\u2013765. https:\/\/doi.org\/10.1002\/pbc.24350","journal-title":"Pediatr Blood Cancer"},{"key":"4501_CR6","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","volume":"2","author":"KK Matthay","year":"2016","unstructured":"Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA (2016) Neuroblastoma Nat Rev Dis Primers 2:16078. https:\/\/doi.org\/10.1038\/nrdp.2016.78","journal-title":"Neuroblastoma Nat Rev Dis Primers"},{"issue":"1","key":"4501_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.hoc.2009.11.011","volume":"24","author":"JR Park","year":"2010","unstructured":"Park JR, Eggert A, Caron H (2010) Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 24(1):65\u201386. https:\/\/doi.org\/10.1016\/j.hoc.2009.11.011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5931","key":"4501_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/305245a0","volume":"305","author":"M Schwab","year":"1983","unstructured":"Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305(5931):245\u2013248. https:\/\/doi.org\/10.1038\/305245a0","journal-title":"Nature"},{"issue":"7215","key":"4501_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nature07261","volume":"455","author":"YP Moss\u00e9","year":"2008","unstructured":"Moss\u00e9 YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215):930\u2013935. https:\/\/doi.org\/10.1038\/nature07261","journal-title":"Nature"},{"issue":"10","key":"4501_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/ng.2387","volume":"44","author":"SJ Diskin","year":"2012","unstructured":"Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, Hou C, Diamond M, Carpenter EL, Winter C, Lee H, Jagannathan J, Latorre V, Iolascon A, Hakonarson H, Devoto M, Maris JM (2012) Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet 44(10):1126\u20131130. https:\/\/doi.org\/10.1038\/ng.2387","journal-title":"Nat Genet"},{"issue":"57","key":"4501_CR11","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1038\/sj.onc.1208157","volume":"23","author":"V van Limpt","year":"2004","unstructured":"van Limpt V, Schramm A, van Lakeman A, Sluis P, Chan A, van Noesel M, Baas F, Caron H, Eggert A, Versteeg R (2004) The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 23(57):9280\u20139288. https:\/\/doi.org\/10.1038\/sj.onc.1208157","journal-title":"Oncogene"},{"issue":"28","key":"4501_CR12","doi-asserted-by":"publisher","first-page":"26335","DOI":"10.18632\/oncotarget.4501","volume":"6","author":"M De Mariano","year":"2015","unstructured":"De Mariano M, Gallesio R, Chierici M, Furlanello C, Conte M, Garaventa A, Croce M, Ferrini S, Tonini GP, Longo L (2015) Identification of GALNT14 as a novel neuroblastoma predisposition gene. Oncotarget 6(28):26335\u201326346. https:\/\/doi.org\/10.18632\/oncotarget.4501","journal-title":"Oncotarget"},{"issue":"4","key":"4501_CR13","first-page":"673","volume":"9","author":"GM Brodeur","year":"1990","unstructured":"Brodeur GM (1990) Neuroblastoma: clinical significance of genetic abnormalities. Cancer Surv 9(4):673\u2013688","journal-title":"Cancer Surv"},{"issue":"1","key":"4501_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/bjc.2015.188","volume":"113","author":"LL Wang","year":"2015","unstructured":"Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H (2015) Augmented expression of MYC and\/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children\u2019s Oncology Group study. Br J Cancer 113(1):57\u201363. https:\/\/doi.org\/10.1038\/bjc.2015.188","journal-title":"Br J Cancer"},{"issue":"2","key":"4501_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1349-7006.2010.01825.x","volume":"102","author":"S Ogawa","year":"2011","unstructured":"Ogawa S, Takita J, Sanada M, Hayashi Y (2011) Oncogenic mutations of ALK in neuroblastoma. Cancer Sci 102(2):302\u2013308. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01825.x","journal-title":"Cancer Sci"},{"issue":"15","key":"4501_CR16","first-page":"3421","volume":"56","author":"JM Maris","year":"1996","unstructured":"Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ, Allen C, Biegel JA, Yanofsky RA, Feldman GL, Brodeur GM (1996) Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res 56(15):3421\u20133425","journal-title":"Cancer Res"},{"issue":"6419","key":"4501_CR17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aat6768","volume":"362","author":"S Ackermann","year":"2018","unstructured":"Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altm\u00fcller J, N\u00fcrnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, B\u00fcttner R, Eggert A, Speleman F, O\u2019Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M (2018) A mechanistic classification of clinical phenotypes in neuroblastoma. Science 362(6419):1165\u20131170. https:\/\/doi.org\/10.1126\/science.aat6768","journal-title":"Science"},{"key":"4501_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2018.12.032","volume":"111","author":"F Herd","year":"2019","unstructured":"Herd F, Basta NO, McNally R, Tweddle DA (2019) A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Eur J Cancer 111:50\u201358. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.032","journal-title":"Eur J Cancer"},{"issue":"27","key":"4501_CR19","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","volume":"33","author":"NR Pinto","year":"2015","unstructured":"Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL (2015) Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol 33(27):3008\u20133017. https:\/\/doi.org\/10.1200\/JCO.2014.59.4648","journal-title":"J Clin Oncol"},{"issue":"5","key":"4501_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/08880018.2017.1373315","volume":"34","author":"D Coughlan","year":"2017","unstructured":"Coughlan D, Gianferante M, Lynch CF, Stevens JL, Harlan LC (2017) Treatment and survival of childhood neuroblastoma: evidence from a population-based study in the United States. Pediatr Hematol Oncol 34(5):320\u2013330. https:\/\/doi.org\/10.1080\/08880018.2017.1373315","journal-title":"Pediatr Hematol Oncol"},{"issue":"9","key":"4501_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/children5090114","volume":"5","author":"V Smith","year":"2018","unstructured":"Smith V, Foster J (2018) High-risk neuroblastoma treatment review Children (Basel) 5(9):114. https:\/\/doi.org\/10.3390\/children5090114","journal-title":"High-risk neuroblastoma treatment review Children (Basel)"},{"issue":"23","key":"4501_CR22","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202\u20132211. https:\/\/doi.org\/10.1056\/NEJMra0804577","journal-title":"N Engl J Med"},{"issue":"1","key":"4501_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14728214.2017.1294159","volume":"22","author":"P Berlanga","year":"2017","unstructured":"Berlanga P, Ca\u00f1ete A, Castel V (2017) Advances in emerging drugs for the treatment of neuroblastoma. Expert Opin Emerg Drugs 22(1):63\u201375. https:\/\/doi.org\/10.1080\/14728214.2017.1294159","journal-title":"Expert Opin Emerg Drugs"},{"issue":"34","key":"4501_CR24","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1200\/JCO.19.00919","volume":"37","author":"CJ Twist","year":"2019","unstructured":"Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL (2019) Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children\u2019s Oncology Group study ANBL0531. J Clin Oncol 37(34):3243\u20133255. https:\/\/doi.org\/10.1200\/JCO.19.00919","journal-title":"J Clin Oncol"},{"issue":"2","key":"4501_CR25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/med.21750","volume":"41","author":"A Zafar","year":"2021","unstructured":"Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F, Foster J, Zhou J, Zhang R (2021) Molecular targeting therapies for neuroblastoma: progress and challenges. Med Res Rev 41(2):961\u20131021. https:\/\/doi.org\/10.1002\/med.21750","journal-title":"Med Res Rev"},{"issue":"9","key":"4501_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00432-007-0216-y","volume":"133","author":"T Simon","year":"2007","unstructured":"Simon T, L\u00e4ngler A, Harnischmacher U, Fr\u00fchwald MC, Jorch N, Claviez A, Berthold F, Hero B (2007) Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol 133(9):653\u2013661. https:\/\/doi.org\/10.1007\/s00432-007-0216-y","journal-title":"J Cancer Res Clin Oncol"},{"issue":"33","key":"4501_CR27","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","volume":"29","author":"JR Park","year":"2011","unstructured":"Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK (2011) Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children\u2019s Oncology Group study. J Clin Oncol 29(33):4351\u20134357. https:\/\/doi.org\/10.1200\/JCO.2010.34.3293","journal-title":"J Clin Oncol"},{"issue":"5","key":"4501_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41581-023-00694-0","volume":"19","author":"AB Sanz","year":"2023","unstructured":"Sanz AB, Sanchez-Ni\u00f1o MD, Ramos AM, Ortiz A (2023) Regulated cell death pathways in kidney disease. Nat Rev Nephrol 19(5):281\u2013299. https:\/\/doi.org\/10.1038\/s41581-023-00694-0","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4501_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40291-018-0329-9","volume":"22","author":"AP Mishra","year":"2018","unstructured":"Mishra AP, Salehi B, Sharifi-Rad M, Pezzani R, Kobarfard F, Sharifi-Rad J, Nigam M (2018) Programmed cell death, from a cancer perspective: an overview. Mol Diagn Ther 22(3):281\u2013295. https:\/\/doi.org\/10.1007\/s40291-018-0329-9","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"4501_CR30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060\u20131072. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042","journal-title":"Cell"},{"issue":"6586","key":"4501_CR31","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, Eaton JK, Frenkel E, Kocak M, Corsello SM, Lutsenko S, Kanarek N, Santagata S, Golub TR (2022) Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 375(6586):1254\u20131261. https:\/\/doi.org\/10.1126\/science.abf0529","journal-title":"Science"},{"issue":"1","key":"4501_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12964-023-01108-1","volume":"21","author":"S Wan","year":"2023","unstructured":"Wan S, Zhang G, Liu R, Abbas MN, Cui H (2023) Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment. Cell Commun Signal 21(1):115. https:\/\/doi.org\/10.1186\/s12964-023-01108-1","journal-title":"Cell Commun Signal"},{"issue":"3","key":"4501_CR33","doi-asserted-by":"publisher","first-page":"e000121","DOI":"10.1136\/wjps-2020-000121","volume":"3","author":"S Huang","year":"2020","unstructured":"Huang S, Gu S (2020) Targeting autophagy in neuroblastoma. World J Pediatr Surg 3(3):e000121. https:\/\/doi.org\/10.1136\/wjps-2020-000121","journal-title":"World J Pediatr Surg"},{"issue":"1","key":"4501_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-022-01365-6","volume":"15","author":"H Wang","year":"2022","unstructured":"Wang H, Zhou X, Li C, Yan S, Feng C, He J, Li Z, Tu C (2022) The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy. J Hematol Oncol 15(1):140. https:\/\/doi.org\/10.1186\/s13045-022-01365-6","journal-title":"J Hematol Oncol"},{"key":"4501_CR35","doi-asserted-by":"publisher","first-page":"1084289","DOI":"10.3389\/fonc.2023.1084289","volume":"13","author":"Y Yao","year":"2023","unstructured":"Yao Y, Ji P, Chen H, Ge J, Xu Y, Wang P, Xu L, Yan Z (2023) Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors. Front Oncol 13:1084289. https:\/\/doi.org\/10.3389\/fonc.2023.1084289","journal-title":"Front Oncol"},{"key":"4501_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04893-y","author":"Q Xu","year":"2023","unstructured":"Xu Q, Ren L, Ren N, Yang Y, Pan J, Zheng Y, Wang G (2023) Ferroptosis: a new promising target for hepatocellular carcinoma therapy. Mol Cell Biochem. https:\/\/doi.org\/10.1007\/s11010-023-04893-y","journal-title":"Mol Cell Biochem"},{"key":"4501_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04886-x","author":"Y Li","year":"2023","unstructured":"Li Y, Liu J, Wu S, Xiao J, Zhang Z (2023) Ferroptosis: opening up potential targets for gastric cancer treatment. Mol Cell Biochem. https:\/\/doi.org\/10.1007\/s11010-023-04886-x","journal-title":"Mol Cell Biochem"},{"issue":"7","key":"4501_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B (2022) Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 22(7):381\u2013396. https:\/\/doi.org\/10.1038\/s41568-022-00459-0","journal-title":"Nat Rev Cancer"},{"key":"4501_CR39","doi-asserted-by":"publisher","first-page":"115015","DOI":"10.1016\/j.ejmech.2022.115015","volume":"247","author":"Y Gu","year":"2023","unstructured":"Gu Y, Li Y, Wang J, Zhang L, Zhang J, Wang Y (2023) Targeting ferroptosis: paving new roads for drug design and discovery. Eur J Med Chem 247:115015. https:\/\/doi.org\/10.1016\/j.ejmech.2022.115015","journal-title":"Eur J Med Chem"},{"key":"4501_CR40","doi-asserted-by":"publisher","unstructured":"Wang Y, Wu S, Li Q, Sun H, Wang H (2023) Pharmacological inhibition of ferroptosis as a therapeutic target for neurodegenerative diseases and strokes. Adv Sci (Weinh) :e2300325. https:\/\/doi.org\/10.1002\/advs.202300325","DOI":"10.1002\/advs.202300325"},{"key":"4501_CR41","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.drup.2022.100916","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wu X, Ren Z, Li Y, Zou W, Chen J, Wang H (2023) Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist Updat 66:100916. https:\/\/doi.org\/10.1016\/j.drup.2022.100916","journal-title":"Drug Resist Updat"},{"key":"4501_CR42","doi-asserted-by":"publisher","first-page":"904152","DOI":"10.3389\/fnagi.2022.904152","volume":"14","author":"Y Sun","year":"2022","unstructured":"Sun Y, Xia X, Basnet D, Zheng JC, Huang J, Liu J (2022) Mechanisms of ferroptosis and emerging links to the pathology of neurodegenerative diseases. Front Aging Neurosci 14:904152. https:\/\/doi.org\/10.3389\/fnagi.2022.904152","journal-title":"Front Aging Neurosci"},{"issue":"7784","key":"4501_CR43","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, Nomura DK, Dixon SJ, Olzmann JA (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575(7784):688\u2013692. https:\/\/doi.org\/10.1038\/s41586-019-1705-2","journal-title":"Nature"},{"issue":"7784","key":"4501_CR44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius E, Scheel CH, Mour\u00e3o A, Buday K, Sato M, Wanninger J, Vignane T, Mohana V, Rehberg M, Flatley A, Schepers A, Kurz A, White D, Sauer M, Sattler M, Tate EW, Schmitz W, Schulze A, O\u2019Donnell V, Proneth B, Popowicz GM, Pratt DA, Angeli J, Conrad M (2019) FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575(7784):693\u2013698. https:\/\/doi.org\/10.1038\/s41586-019-1707-0","journal-title":"Nature"},{"issue":"1","key":"4501_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","volume":"6","author":"V Kraft","year":"2020","unstructured":"Kraft V, Bezjian CT, Pfeiffer S, Ringelstetter L, M\u00fcller C, Zandkarimi F, Merl-Pham J, Bao X, Anastasov N, K\u00f6ssl J, Brandner S, Daniels JD, Schmitt-Kopplin P, Hauck SM, Stockwell BR, Hadian K, Schick JA (2020) GTP cyclohydrolase 1\/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci 6(1):41\u201353. https:\/\/doi.org\/10.1021\/acscentsci.9b01063","journal-title":"ACS Cent Sci"},{"issue":"12","key":"4501_CR46","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41589-020-0613-y","volume":"16","author":"M Soula","year":"2020","unstructured":"Soula M, Weber RA, Zilka O, Alwaseem H, La K, Yen F, Molina H, Garcia-Bermudez J, Pratt DA, Birsoy K (2020) Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nat Chem Biol 16(12):1351\u20131360. https:\/\/doi.org\/10.1038\/s41589-020-0613-y","journal-title":"Nat Chem Biol"},{"issue":"7860","key":"4501_CR47","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, Koppula P, Wu S, Zhuang L, Fang B, Poyurovsky MV, Olszewski K, Gan B (2021) DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593(7860):586\u2013590. https:\/\/doi.org\/10.1038\/s41586-021-03539-7","journal-title":"Nature"},{"key":"4501_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.05.003","author":"D Liang","year":"2023","unstructured":"Liang D, Feng Y, Zandkarimi F, Wang H, Zhang Z, Kim J, Cai Y, Gu W, Stockwell BR, Jiang X (2023) Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell. https:\/\/doi.org\/10.1016\/j.cell.2023.05.003","journal-title":"Cell"},{"key":"4501_CR49","doi-asserted-by":"publisher","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021) Ferroptosis in infection, inflammation, and immunity. J Exp Med. 218(6). https:\/\/doi.org\/10.1084\/jem.20210518","DOI":"10.1084\/jem.20210518"},{"issue":"9","key":"4501_CR50","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D (2021) Ferroptosis: machinery and regulation. Autophagy 17(9):2054\u20132081. https:\/\/doi.org\/10.1080\/15548627.2020.1810918","journal-title":"Autophagy"},{"issue":"12","key":"4501_CR51","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.molcel.2022.03.022","volume":"82","author":"D Liang","year":"2022","unstructured":"Liang D, Minikes AM, Jiang X (2022) Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell 82(12):2215\u20132227. https:\/\/doi.org\/10.1016\/j.molcel.2022.03.022","journal-title":"Mol Cell"},{"issue":"5","key":"4501_CR52","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.cell.2020.04.039","volume":"181","author":"K Hadian","year":"2020","unstructured":"Hadian K, Stockwell BR (2020) SnapShot: ferroptosis. Cell 181(5):1188-1188.e1. https:\/\/doi.org\/10.1016\/j.cell.2020.04.039","journal-title":"Cell"},{"issue":"7","key":"4501_CR53","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1021\/acschembio.5b00245","volume":"10","author":"SJ Dixon","year":"2015","unstructured":"Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, Superti-Furga G, Stockwell BR (2015) Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol 10(7):1604\u20131609. https:\/\/doi.org\/10.1021\/acschembio.5b00245","journal-title":"ACS Chem Biol"},{"issue":"1","key":"4501_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Tr\u00fcmbach D, Mao G, Qu F, Bayir H, F\u00fcllekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JP, Conrad M (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13(1):91\u201398. https:\/\/doi.org\/10.1038\/nchembio.2239","journal-title":"Nat Chem Biol"},{"issue":"1","key":"4501_CR55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, Kapralov AA, Amoscato AA, Jiang J, Anthonymuthu T, Mohammadyani D, Yang Q, Proneth B, Klein-Seetharaman J, Watkins S, Bahar I, Greenberger J, Mallampalli RK, Stockwell BR, Tyurina YY, Conrad M, Bay\u0131r H (2017) Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 13(1):81\u201390. https:\/\/doi.org\/10.1038\/nchembio.2238","journal-title":"Nat Chem Biol"},{"issue":"3","key":"4501_CR56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41589-020-0472-6","volume":"16","author":"Y Zou","year":"2020","unstructured":"Zou Y, Li H, Graham ET, Deik AA, Eaton JK, Wang W, Sandoval-Gomez G, Clish CB, Doench JG, Schreiber SL (2020) Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat Chem Biol 16(3):302\u2013309. https:\/\/doi.org\/10.1038\/s41589-020-0472-6","journal-title":"Nat Chem Biol"},{"issue":"21","key":"4501_CR57","doi-asserted-by":"publisher","first-page":"R1292","DOI":"10.1016\/j.cub.2020.09.068","volume":"30","author":"D Tang","year":"2020","unstructured":"Tang D, Kroemer G (2020) Ferroptosis. Curr Biol 30(21):R1292\u2013R1297. https:\/\/doi.org\/10.1016\/j.cub.2020.09.068","journal-title":"Curr Biol"},{"issue":"9","key":"4501_CR58","doi-asserted-by":"publisher","first-page":"R421","DOI":"10.1016\/j.cub.2021.03.054","volume":"31","author":"T Tsang","year":"2021","unstructured":"Tsang T, Davis CI, Brady DC (2021) Copper biology. Curr Biol 31(9):R421\u2013R427. https:\/\/doi.org\/10.1016\/j.cub.2021.03.054","journal-title":"Curr Biol"},{"issue":"1","key":"4501_CR59","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","volume":"7","author":"L Chen","year":"2022","unstructured":"Chen L, Min J, Wang F (2022) Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther 7(1):378. https:\/\/doi.org\/10.1038\/s41392-022-01229-y","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4501_CR60","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41418-023-01125-0","volume":"30","author":"C Xiong","year":"2023","unstructured":"Xiong C, Ling H, Hao Q, Zhou X (2023) Cuproptosis: p53-regulated metabolic cell death. Cell Death Differ 30(4):876\u2013884. https:\/\/doi.org\/10.1038\/s41418-023-01125-0","journal-title":"Cell Death Differ"},{"issue":"2","key":"4501_CR61","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","volume":"22","author":"EJ Ge","year":"2022","unstructured":"Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, Dou QP, Franz KJ, Gohil VM, Gupta S, Kaler SG, Lutsenko S, Mittal V, Petris MJ, Polishchuk R, Ralle M, Schilsky ML, Tonks NK, Vahdat LT, Van Aelst L, Xi D, Yuan P, Brady DC, Chang CJ (2022) Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer 22(2):102\u2013113. https:\/\/doi.org\/10.1038\/s41568-021-00417-2","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4501_CR62","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","volume":"15","author":"P Tsvetkov","year":"2019","unstructured":"Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, Kocak M, Kory N, Tsherniak A, Santagata S, Whitesell L, Ghobrial IM, Markley JL, Lindquist S, Golub TR (2019) Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol 15(7):681\u2013689. https:\/\/doi.org\/10.1038\/s41589-019-0291-9","journal-title":"Nat Chem Biol"},{"issue":"5","key":"4501_CR63","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000455548","volume":"1","author":"NG Beratis","year":"1980","unstructured":"Beratis NG, Yee M, LaBadie GU, Hirschhorn K (1980) Effect of copper on Menkes\u2019 and normal cultured skin fibroblasts. Dev Pharmacol Ther 1(5):305\u2013317","journal-title":"Dev Pharmacol Ther"},{"issue":"3","key":"4501_CR64","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/jnci\/80.3.188","volume":"80","author":"ME B\u00e9gin","year":"1988","unstructured":"B\u00e9gin ME, Ells G, Horrobin DF (1988) Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst 80(3):188\u2013194. https:\/\/doi.org\/10.1093\/jnci\/80.3.188","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"4501_CR65","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/WNR.0000000000001467","volume":"31","author":"Q Lin","year":"2020","unstructured":"Lin Q, Hou S, Dai Y, Jiang N, Lin Y (2020) Monascin exhibits neuroprotective effects in rotenone model of Parkinson\u2019s disease via antioxidation and anti-neuroinflammation. Neuroreport 31(9):637\u2013643. https:\/\/doi.org\/10.1097\/WNR.0000000000001467","journal-title":"Neuroreport"},{"issue":"4","key":"4501_CR66","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3390\/cancers15041301","volume":"15","author":"X Li","year":"2023","unstructured":"Li X, Wang Q, Xu C, Zhang L, Zhou J, Lv J, Xu M, Jiang D (2023) Ferroptosis inducers kill mesenchymal stem cells affected by neuroblastoma. Cancers (Basel) 15(4):1301. https:\/\/doi.org\/10.3390\/cancers15041301","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4501_CR67","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.freeradbiomed.2012.03.017","volume":"52","author":"M Nagai","year":"2012","unstructured":"Nagai M, Vo NH, Shin Ogawa L, Chimmanamada D, Inoue T, Chu J, Beaudette-Zlatanova BC, Lu R, Blackman RK, Barsoum J, Koya K, Wada Y (2012) The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med 52(10):2142\u20132150. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.03.017","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"4501_CR68","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1002\/1878-0261.13079","volume":"15","author":"W Gao","year":"2021","unstructured":"Gao W, Huang Z, Duan J, Nice EC, Lin J, Huang C (2021) Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A. Mol Oncol 15(12):3527\u20133544. https:\/\/doi.org\/10.1002\/1878-0261.13079","journal-title":"Mol Oncol"},{"key":"4501_CR69","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.drup.2023.101018","volume":"72","author":"Y Wang","year":"2023","unstructured":"Wang Y, Chen Y, Zhang J, Yang Y, Fleishman JS, Wang Y, Wang J, Chen J, Li Y, Wang H (2023) Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance. Drug Resist Updat 72:101018. https:\/\/doi.org\/10.1016\/j.drup.2023.101018","journal-title":"Drug Resist Updat"},{"issue":"7","key":"4501_CR70","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/0008-5472.CAN-20-1641","volume":"81","author":"KV Floros","year":"2021","unstructured":"Floros KV, Cai J, Jacob S, Kurupi R, Fairchild CK, Shende M, Coon CM, Powell KM, Belvin BR, Hu B, Puchalapalli M, Ramamoorthy S, Swift K, Lewis JP, Dozmorov MG, Glod J, Koblinski JE, Boikos SA, Faber AC (2021) MYCN-amplified neuroblastoma is addicted to iron and vulnerable to inhibition of the system Xc-\/glutathione axis. Cancer Res 81(7):1896\u20131908. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1641","journal-title":"Cancer Res"},{"issue":"6","key":"4501_CR71","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41419-021-03790-w","volume":"12","author":"Y Lu","year":"2021","unstructured":"Lu Y, Yang Q, Su Y, Ji Y, Li G, Yang X, Xu L, Lu Z, Dong J, Wu Y, Bei JX, Pan C, Gu X, Li B (2021) MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma. Cell Death Dis 12(6):511. https:\/\/doi.org\/10.1038\/s41419-021-03790-w","journal-title":"Cell Death Dis"},{"issue":"4","key":"4501_CR72","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s43018-022-00355-4","volume":"3","author":"H Alborzinia","year":"2022","unstructured":"Alborzinia H, Fl\u00f3rez AF, Kreth S, Br\u00fcckner LM, Yildiz U, Gartlgruber M, Odoni DI, Poschet G, Garbowicz K, Shao C, Klein C, Meier J, Zeisberger P, Nadler-Holly M, Ziehm M, Paul F, Burhenne J, Bell E, Shaikhkarami M, W\u00fcrth R, Stainczyk SA, Wecht EM, Kreth J, B\u00fcttner M, Ishaque N, Schlesner M, Nicke B, Stresemann C, Llamazares-Prada M, Reiling JH, Fischer M, Amit I, Selbach M, Herrmann C, W\u00f6lfl S, Henrich KO, H\u00f6fer T, Trumpp A, Westermann F (2022) MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer 3(4):471\u2013485. https:\/\/doi.org\/10.1038\/s43018-022-00355-4","journal-title":"Nat Cancer"},{"issue":"2","key":"4501_CR73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.15698\/cst2022.02.264","volume":"6","author":"KV Floros","year":"2022","unstructured":"Floros KV, Chawla AT, Johnson-Berro MO, Khatri R, Stamatouli AM, Boikos SA, Dozmorov MG, Cowart LA, Faber AC (2022) MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma. Cell Stress 6(2):21\u201329. https:\/\/doi.org\/10.15698\/cst2022.02.264","journal-title":"Cell Stress"},{"issue":"8","key":"4501_CR74","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.15252\/emmm.202318014","volume":"15","author":"H Alborzinia","year":"2023","unstructured":"Alborzinia H, Chen Z, Yildiz U, Freitas FP, Vogel F, Varga JP, Batani J, Bartenhagen C, Schmitz W, B\u00fcchel G, Michalke B, Zheng J, Meierjohann S, Girardi E, Espinet E, Fl\u00f3rez AF, Dos Santos AF, Aroua N, Cheytan T, Haenlin J, Schlicker L, Xavier da Silva TN, Przybylla A, Zeisberger P, Superti-Furga G, Eilers M, Conrad M, Fabiano M, Schweizer U, Fischer M, Schulze A, Trumpp A, Friedmann Angeli JP (2023) LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma. EMBO Mol Med 15(8):18014. https:\/\/doi.org\/10.15252\/emmm.202318014","journal-title":"EMBO Mol Med"},{"issue":"4","key":"4501_CR75","doi-asserted-by":"publisher","first-page":"e26014","DOI":"10.1016\/j.heliyon.2024.e26014","volume":"10","author":"Y Liu","year":"2024","unstructured":"Liu Y, Jiang N, Chen W, Zhang W, Shen X, Jia B, Chen G (2024) TRIM59-mediated ferroptosis enhances neuroblastoma development and chemosensitivity through p53 ubiquitination and degradation. Heliyon 10(4):e26014. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26014","journal-title":"Heliyon"},{"key":"4501_CR76","doi-asserted-by":"publisher","first-page":"999849","DOI":"10.3389\/fimmu.2022.999849","volume":"13","author":"XM Tian","year":"2022","unstructured":"Tian XM, Xiang B, Yu YH, Li Q, Zhang ZX, Zhanghuang C, Jin LM, Wang JK, Mi T, Chen ML, Liu F, Wei GH (2022) A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma. Front Immunol 13:999849. https:\/\/doi.org\/10.3389\/fimmu.2022.999849","journal-title":"Front Immunol"},{"key":"4501_CR77","doi-asserted-by":"publisher","first-page":"1049858","DOI":"10.3389\/fped.2022.1049858","volume":"10","author":"H Yang","year":"2022","unstructured":"Yang H, Yang J, Bian H, Wang X (2022) A novel cuproptosis-related gene signature predicting overall survival in pediatric neuroblastoma patients. Front Pediatr 10:1049858. https:\/\/doi.org\/10.3389\/fped.2022.1049858","journal-title":"Front Pediatr"},{"issue":"1","key":"4501_CR78","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s12864-023-09699-2","volume":"24","author":"R Zhou","year":"2023","unstructured":"Zhou R, Huang D, Fu W, Shu F (2023) Comprehensive exploration of the involvement of cuproptosis in tumorigenesis and progression of neuroblastoma. BMC Genomics 24(1):715. https:\/\/doi.org\/10.1186\/s12864-023-09699-2","journal-title":"BMC Genomics"},{"issue":"14","key":"4501_CR79","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.3390\/ijms21144908","volume":"21","author":"MM Capelletti","year":"2020","unstructured":"Capelletti MM, Manceau H, PuyPeoc\u2019h HK (2020) Ferroptosis in liver diseases: an overview. Int J Mol Sci 21(14):4908. https:\/\/doi.org\/10.3390\/ijms21144908","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4501_CR80","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s12272-020-01273-8","volume":"43","author":"KM Kim","year":"2020","unstructured":"Kim KM, Cho SS, Ki SH (2020) Emerging roles of ferroptosis in liver pathophysiology. Arch Pharm Res 43(10):985\u2013996. https:\/\/doi.org\/10.1007\/s12272-020-01273-8","journal-title":"Arch Pharm Res"},{"issue":"1\u20133","key":"4501_CR81","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1089\/ars.2023.0356","volume":"39","author":"D Tang","year":"2023","unstructured":"Tang D, Kang R (2023) From oxytosis to ferroptosis: 10 years of research on oxidative cell death. Antioxid Redox Signal 39(1\u20133):162\u2013165. https:\/\/doi.org\/10.1089\/ars.2023.0356","journal-title":"Antioxid Redox Signal"},{"issue":"16","key":"4501_CR82","doi-asserted-by":"publisher","first-page":"8898","DOI":"10.3390\/ijms22168898","volume":"22","author":"R Lu","year":"2021","unstructured":"Lu R, Jiang Y, Lai X, Liu S, Sun L, Zhou ZW (2021) A shortage of FTH induces ROS and sensitizes RAS-proficient neuroblastoma N2A cells to ferroptosis. Int J Mol Sci 22(16):8898. https:\/\/doi.org\/10.3390\/ijms22168898","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4501_CR83","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","volume":"15","author":"PW Gout","year":"2001","unstructured":"Gout PW, Buckley AR, Simms CR, Bruchovsky N (2001) Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15(10):1633\u20131640. https:\/\/doi.org\/10.1038\/sj.leu.2402238","journal-title":"Leukemia"},{"issue":"5","key":"4501_CR84","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI992","volume":"101","author":"C Wahl","year":"1998","unstructured":"Wahl C, Liptay S, Adler G, Schmid RM (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101(5):1163\u20131174. https:\/\/doi.org\/10.1172\/JCI992","journal-title":"J Clin Invest"},{"key":"4501_CR85","doi-asserted-by":"publisher","unstructured":"Monteleone L, Speciale A, Valenti GE, Traverso N, Ravera S, Garbarino O, Leardi R, Farinini E, Roveri A, Ursini F, Cantoni C, Pronzato MA, Marinari UM, Marengo B, Domenicotti C (2021) PKC\u03b1 inhibition as a strategy to sensitize neuroblastoma stem cells to etoposide by stimulating ferroptosis. Antioxidants (Basel) 10(5). https:\/\/doi.org\/10.3390\/antiox10050691","DOI":"10.3390\/antiox10050691"},{"issue":"1","key":"4501_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/antiox13010003","volume":"13","author":"GE Valenti","year":"2023","unstructured":"Valenti GE, Roveri A, Venerando R, Menichini P, Monti P, Tasso B, Traverso N, Domenicotti C, Marengo B (2023) PTC596-induced BMI-1 inhibition fights neuroblastoma multidrug resistance by inducing ferroptosis. Antioxidants (Basel) 13(1):3. https:\/\/doi.org\/10.3390\/antiox13010003","journal-title":"Antioxidants (Basel)"},{"key":"4501_CR87","doi-asserted-by":"publisher","first-page":"113674","DOI":"10.1016\/j.phytochem.2023.113674","volume":"210","author":"O Cuesta-Rubio","year":"2023","unstructured":"Cuesta-Rubio O, Monzote L, Fern\u00e1ndez-Acosta R, Pardo-Andreu GL, Rastrelli L (2023) A review of nemorosone: chemistry and biological properties. Phytochemistry 210:113674. https:\/\/doi.org\/10.1016\/j.phytochem.2023.113674","journal-title":"Phytochemistry"},{"issue":"9","key":"4501_CR88","doi-asserted-by":"publisher","first-page":"e74555","DOI":"10.1371\/journal.pone.0074555","volume":"8","author":"RJ Wolf","year":"2013","unstructured":"Wolf RJ, Hilger RA, Hoheisel JD, Werner J, Holtrup F (2013) In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts. PLoS ONE 8(9):e74555. https:\/\/doi.org\/10.1371\/journal.pone.0074555","journal-title":"PLoS ONE"},{"issue":"1","key":"4501_CR89","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.phymed.2014.11.007","volume":"22","author":"MS Camargo","year":"2015","unstructured":"Camargo MS, Oliveira MT, Santoni MM, Resende FA, Oliveira-H\u00f6hne AP, Espanha LG, Nogueira CH, Cuesta-Rubio O, Vilegas W, Varanda EA (2015) Effects of nemorosone, isolated from the plant Clusia rosea, on the cell cycle and gene expression in MCF-7 BUS breast cancer cell lines. Phytomedicine 22(1):153\u2013157. https:\/\/doi.org\/10.1016\/j.phymed.2014.11.007","journal-title":"Phytomedicine"},{"key":"4501_CR90","doi-asserted-by":"publisher","first-page":"116817","DOI":"10.1016\/j.lfs.2019.116817","volume":"235","author":"Y Fri\u00f3n-Herrera","year":"2019","unstructured":"Fri\u00f3n-Herrera Y, Gabbia D, Cuesta-Rubio O, De Martin S, Carrara M (2019) Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells. Life Sci 235:116817. https:\/\/doi.org\/10.1016\/j.lfs.2019.116817","journal-title":"Life Sci"},{"key":"4501_CR91","doi-asserted-by":"publisher","first-page":"104173","DOI":"10.1016\/j.fitote.2019.104173","volume":"136","author":"Y Fri\u00f3n-Herrera","year":"2019","unstructured":"Fri\u00f3n-Herrera Y, Gabbia D, D\u00edaz-Garc\u00eda A, Cuesta-Rubio O, Carrara M (2019) Chemosensitizing activity of Cuban propolis and nemorosone in doxorubicin resistant human colon carcinoma cells. Fitoterapia 136:104173. https:\/\/doi.org\/10.1016\/j.fitote.2019.104173","journal-title":"Fitoterapia"},{"issue":"7","key":"4501_CR92","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3390\/nu12072040","volume":"12","author":"Y Fri\u00f3n-Herrera","year":"2020","unstructured":"Fri\u00f3n-Herrera Y, Gabbia D, Scaffidi M, Zagni L, Cuesta-Rubio O, De Martin S, Carrara M (2020) Cuban brown propolis interferes in the crosstalk between colorectal cancer cells and M2 macrophages. Nutrients 12(7):2040. https:\/\/doi.org\/10.3390\/nu12072040","journal-title":"Nutrients"},{"issue":"5","key":"4501_CR93","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/ijms21051827","volume":"21","author":"Y Fri\u00f3n-Herrera","year":"2020","unstructured":"Fri\u00f3n-Herrera Y, Gabbia D, Scaffidi M, Zagni L, Cuesta-Rubio O, De Martin S, Carrara M (2020) The Cuban propolis component nemorosone inhibits Proliferation and metastatic properties of human colorectal cancer cells. Int J Mol Sci 21(5):1827. https:\/\/doi.org\/10.3390\/ijms21051827","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4501_CR94","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/cells12050735","volume":"12","author":"R Fern\u00e1ndez-Acosta","year":"2023","unstructured":"Fern\u00e1ndez-Acosta R, Hassannia B, Caroen J, Wiernicki B, Alvarez-Alminaque D, Verstraeten B, Van der Eycken J, Vandenabeele P, Vanden Berghe T, Pardo-Andreu GL (2023) Molecular mechanisms of nemorosone-induced ferroptosis in cancer cells. Cells 12(5):735. https:\/\/doi.org\/10.3390\/cells12050735","journal-title":"Cells"},{"issue":"1","key":"4501_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-013-9531-1","volume":"16","author":"AR Vyas","year":"2014","unstructured":"Vyas AR, Singh SV (2014) Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone. AAPS J 16(1):1\u201310. https:\/\/doi.org\/10.1208\/s12248-013-9531-1","journal-title":"AAPS J"},{"issue":"7","key":"4501_CR96","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1080\/15384047.2015.1046651","volume":"16","author":"MK McKenna","year":"2015","unstructured":"McKenna MK, Gachuki BW, Alhakeem SS, Oben KN, Rangnekar VM, Gupta RC, Bondada S (2015) Anti-cancer activity of withaferin A in B-cell lymphoma. Cancer Biol Ther 16(7):1088\u20131098. https:\/\/doi.org\/10.1080\/15384047.2015.1046651","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"4501_CR97","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2174\/1386207320666170112141833","volume":"20","author":"R Mahadevappa","year":"2017","unstructured":"Mahadevappa R, Kwok HF (2017) Phytochemicals - a novel and prominent source of anti-cancer drugs against colorectal cancer. Comb Chem High Throughput Screen 20(5):376\u2013394. https:\/\/doi.org\/10.2174\/1386207320666170112141833","journal-title":"Comb Chem High Throughput Screen"},{"issue":"1","key":"4501_CR98","first-page":"332","volume":"25","author":"X Yin","year":"2020","unstructured":"Yin X, Yang G, Ma D, Su Z (2020) Inhibition of cancer cell growth in cisplatin-resistant human oral cancer cells by withaferin-A is mediated via both apoptosis and autophagic cell death, endogenous ROS production, G2\/M phase cell cycle arrest and by targeting MAPK\/RAS\/RAF signalling pathway. J BUON 25(1):332\u2013337","journal-title":"J BUON"},{"issue":"9","key":"4501_CR99","doi-asserted-by":"publisher","first-page":"841","DOI":"10.6026\/97320630018841","volume":"18","author":"TS Meghalatha","year":"2022","unstructured":"Meghalatha TS, Muninathan N (2022) Antitumor activity of withaferin-A and propolis in benz (a) pyrene-induced breast cancer. Bioinformation 18(9):841\u2013844. https:\/\/doi.org\/10.6026\/97320630018841","journal-title":"Bioinformation"},{"key":"4501_CR100","doi-asserted-by":"publisher","DOI":"10.2174\/1566524023666230418094708","author":"P Abeesh","year":"2023","unstructured":"Abeesh P, Guruvayoorappan C (2023) The therapeutic effects of withaferin A against cancer: overview and updates. Curr Mol Med. https:\/\/doi.org\/10.2174\/1566524023666230418094708","journal-title":"Curr Mol Med"},{"issue":"12","key":"4501_CR101","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3390\/cancers15123089","volume":"15","author":"R Khalil","year":"2023","unstructured":"Khalil R, Green RJ, Sivakumar K, Varandani P, Bharadwaj S, Mohapatra SS, Mohapatra S (2023) Withaferin A increases the effectiveness of immune checkpoint blocker for the treatment of non-small cell lung cancer. Cancers (Basel) 15(12):3089. https:\/\/doi.org\/10.3390\/cancers15123089","journal-title":"Cancers (Basel)"},{"key":"4501_CR102","doi-asserted-by":"publisher","DOI":"10.2174\/1568026623666230726105017","author":"V Kumar","year":"2023","unstructured":"Kumar V, Dhanjal JK, Sari AN, Khurana M, Kaul SC, Wadhwa R, Sundar D (2023) Effect of withaferin-A, withanone, and caffeic acid phenethyl ester on DNA methyltransferases: potential in epigenetic cancer therapy. Curr Top Med Chem. https:\/\/doi.org\/10.2174\/1568026623666230726105017","journal-title":"Curr Top Med Chem"},{"key":"4501_CR103","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.2147\/DDDT.S422512","volume":"17","author":"Z Xing","year":"2023","unstructured":"Xing Z, Su A, Mi L, Zhang Y, He T, Qiu Y, Wei T, Li Z, Zhu J, Wu W (2023) Withaferin A: a dietary supplement with promising potential as an anti-tumor therapeutic for cancer treatment - pharmacology and mechanisms. Drug Des Devel Ther 17:2909\u20132929. https:\/\/doi.org\/10.2147\/DDDT.S422512","journal-title":"Drug Des Devel Ther"},{"key":"4501_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/BCI.S18863","volume":"7","author":"LP Yco","year":"2014","unstructured":"Yco LP, Mocz G, Opoku-Ansah J, Bachmann AS (2014) Withaferin A inhibits STAT3 and induces tumor cell death in neuroblastoma and multiple myeloma. Biochem Insights 7:1\u201313. https:\/\/doi.org\/10.4137\/BCI.S18863","journal-title":"Biochem Insights"},{"issue":"8","key":"4501_CR105","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1172\/JCI99032","volume":"128","author":"B Hassannia","year":"2018","unstructured":"Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, Bay\u0131r H, Abhari BA, Angeli J, Choi SM, Meul E, Heyninck K, Declerck K, Chirumamilla CS, Lahtela-Kakkonen M, Van Camp G, Krysko DV, Ekert PG, Fulda S, De Geest BG, Conrad M, Kagan VE, Vanden Berghe W, Vandenabeele P, Vanden Berghe T (2018) Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J Clin Invest 128(8):3341\u20133355. https:\/\/doi.org\/10.1172\/JCI99032","journal-title":"J Clin Invest"},{"issue":"13","key":"4501_CR106","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/molecules27133970","volume":"27","author":"R Fern\u00e1ndez-Acosta","year":"2022","unstructured":"Fern\u00e1ndez-Acosta R, Iriarte-Mesa C, Alvarez-Alminaque D, Hassannia B, Wiernicki B, D\u00edaz-Garc\u00eda AM, Vandenabeele P, Vanden Berghe T, Pardo Andreu GL (2022) Novel iron oxide nanoparticles induce ferroptosis in a panel of cancer cell lines. Molecules 27(13):3970. https:\/\/doi.org\/10.3390\/molecules27133970","journal-title":"Molecules"},{"key":"4501_CR107","doi-asserted-by":"publisher","first-page":"1288504","DOI":"10.3389\/fonc.2023.1288504","volume":"13","author":"M Wang","year":"2023","unstructured":"Wang M, Zheng L, Ma S, Lin R, Li J, Yang S (2023) Cuproptosis: emerging biomarkers and potential therapeutics in cancers. Front Oncol 13:1288504. https:\/\/doi.org\/10.3389\/fonc.2023.1288504","journal-title":"Front Oncol"},{"key":"4501_CR108","doi-asserted-by":"publisher","first-page":"114301","DOI":"10.1016\/j.biopha.2023.114301","volume":"159","author":"W Yang","year":"2023","unstructured":"Yang W, Wang Y, Huang Y, Yu J, Wang T, Li C, Yang L, Zhang P, Shi L, Yin Y, Tao K, Li R (2023) 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer. Biomed Pharmacother 159:114301. https:\/\/doi.org\/10.1016\/j.biopha.2023.114301","journal-title":"Biomed Pharmacother"},{"issue":"14","key":"4501_CR109","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.7150\/jca.77445","volume":"13","author":"X Nie","year":"2022","unstructured":"Nie X, Chen H, Xiong Y, Chen J, Liu T (2022) Anisomycin has a potential toxicity of promoting cuproptosis in human ovarian cancer stem cells by attenuating YY1\/lipoic acid pathway activation. J Cancer 13(14):3503\u20133514. https:\/\/doi.org\/10.7150\/jca.77445","journal-title":"J Cancer"},{"key":"4501_CR110","doi-asserted-by":"publisher","first-page":"1036408","DOI":"10.3389\/fgene.2022.1036408","volume":"13","author":"K Fan","year":"2022","unstructured":"Fan K, Dong Y, Li T, Li Y (2022) Cuproptosis-associated CDKN2A is targeted by plicamycin to regulate the microenvironment in patients with head and neck squamous cell carcinoma. Front Genet 13:1036408. https:\/\/doi.org\/10.3389\/fgene.2022.1036408","journal-title":"Front Genet"},{"issue":"1","key":"4501_CR111","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-023-02720-2","volume":"42","author":"W Wang","year":"2023","unstructured":"Wang W, Lu K, Jiang X, Wei Q, Zhu L, Wang X, Jin H, Feng L (2023) Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. J Exp Clin Cancer Res 42(1):142. https:\/\/doi.org\/10.1186\/s13046-023-02720-2","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"4501_CR112","doi-asserted-by":"publisher","first-page":"108218","DOI":"10.1016\/j.isci.2023.108218","volume":"26","author":"X Yang","year":"2023","unstructured":"Yang X, Deng L, Diao X, Yang S, Zou L, Yang Q, Li J, Nie J, Zhao L, Jiao B (2023) Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer. IScience 26(11):108218. https:\/\/doi.org\/10.1016\/j.isci.2023.108218","journal-title":"IScience"},{"key":"4501_CR113","doi-asserted-by":"publisher","first-page":"1252567","DOI":"10.3389\/fphar.2023.1252567","volume":"14","author":"N Ta","year":"2023","unstructured":"Ta N, Jiang X, Zhang Y, Wang H (2023) Ferroptosis as a promising therapeutic strategy for melanoma. Front Pharmacol 14:1252567. https:\/\/doi.org\/10.3389\/fphar.2023.1252567","journal-title":"Front Pharmacol"},{"key":"4501_CR114","doi-asserted-by":"publisher","unstructured":"Vinik Y, Maimon A, Dubey V, Raj H, Abramovitch I, Malitsky S, Itkin M, Ma\u2019ayan A, Westermann F, Gottlieb E, Ruppin E, Lev S (2024) Programming a ferroptosis-to-apoptosis transition landscape revealed ferroptosis biomarkers and repressors for cancer therapy. Adv Sci (Weinh) :e2307263. https:\/\/doi.org\/10.1002\/advs.202307263","DOI":"10.1002\/advs.202307263"},{"key":"4501_CR115","doi-asserted-by":"publisher","first-page":"774458","DOI":"10.3389\/fonc.2022.774458","volume":"12","author":"L Qiu","year":"2022","unstructured":"Qiu L, Zhou R, Luo Z, Wu J, Jiang H (2022) CDC27-ODC1 axis promotes metastasis, accelerates ferroptosis and predicts poor prognosis in neuroblastoma. Front Oncol 12:774458. https:\/\/doi.org\/10.3389\/fonc.2022.774458","journal-title":"Front Oncol"},{"issue":"1","key":"4501_CR116","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12967-023-04802-3","volume":"22","author":"L Yuhan","year":"2024","unstructured":"Yuhan L, Khaleghi Ghadiri M, Gorji A (2024) Impact of NQO1 dysregulation in CNS disorders. J Transl Med 22(1):4. https:\/\/doi.org\/10.1186\/s12967-023-04802-3","journal-title":"J Transl Med"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04501-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-024-04501-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04501-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:03:57Z","timestamp":1738562637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-024-04501-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":116,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["4501"],"URL":"https:\/\/doi.org\/10.1007\/s12035-024-04501-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}